Lipid-based formulations have re-emerged as oral drug delivery systems. Advances in the techniques to evaluate the in vivo fate of the formulations, together with an improved knowledge of the gastrointestinal processes/barriers to the evolving lipid-based systems, could explain, at least partially, this revival. In addition, the use of lipid-based formulations is no longer limited to highly lipophilic drugs and has been extended to hydrophilic peptides and macromolecules. Last but not least, (targeted) nanocarriers have been developed exploiting gut physiology toward novel targets in the field. We herein review what we believe have been the major advances in oral drug delivery via lipid-based formulations in recent years, leading to their re-emergence as promising drug delivery systems for future clinical application.

基于脂质的制剂已经作为口服药物递送系统重新出现。在技术的进步，以评估在 体内配制剂的命运以及对基于脂质的系统不断发展的胃肠道过程/屏障的了解，可以至少部分地解释了这种复兴。另外，基于脂质的制剂的使用不再限于高度亲脂性药物，并且已经扩展到亲水性肽和大分子。最后但并非最不重要的一点是，已经开发了（靶向）纳米载体，其利用肠道生理学向本领域的新​​型靶标发展。我们在此回顾了我们认为近年来通过基于脂质的制剂在口服药物递送方面的主要进展，从而使它们重新出现，成为未来临床应用的有希望的药物递送系统。